Logo image of PRCT

PROCEPT BIOROBOTICS CORP (PRCT) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:PRCT - US74276L1052 - Common Stock

31.455 USD
+0.88 (+2.86%)
Last: 1/14/2026, 3:56:55 PM

PRCT Key Statistics, Chart & Performance

Key Statistics
Market Cap1.76B
Revenue(TTM)299.91M
Net Income(TTM)-84.58M
Shares55.88M
Float53.40M
52 Week High76.95
52 Week Low27.8
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-1.53
PEN/A
Fwd PEN/A
Earnings (Next)02-23
IPO2021-09-15
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
PRCT short term performance overview.The bars show the price performance of PRCT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

PRCT long term performance overview.The bars show the price performance of PRCT in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of PRCT is 31.455 USD. In the past month the price decreased by -15.03%. In the past year, price decreased by -59.77%.

PROCEPT BIOROBOTICS CORP / PRCT Daily stock chart

PRCT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

PRCT Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to PRCT. The financial health of PRCT is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PRCT Financial Highlights

Over the last trailing twelve months PRCT reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS increased by 21.54% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -16.53%
ROE -22.24%
Debt/Equity 0.14
Chartmill High Growth Momentum
EPS Q2Q%5%
Sales Q2Q%42.76%
EPS 1Y (TTM)21.54%
Revenue 1Y (TTM)50.07%

PRCT Forecast & Estimates

20 analysts have analysed PRCT and the average price target is 53.81 USD. This implies a price increase of 71.05% is expected in the next year compared to the current price of 31.455.

For the next year, analysts expect an EPS growth of 12.5% and a revenue growth 46.32% for PRCT


Analysts
Analysts82
Price Target53.81 (71.07%)
EPS Next Y12.5%
Revenue Next Year46.32%

PRCT Ownership

Ownership
Inst Owners106.65%
Ins Owners4.23%
Short Float %11.39%
Short Ratio4.03

About PRCT

Company Profile

PRCT logo image PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 756 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.

Company Info

PROCEPT BIOROBOTICS CORP

150 Baytech Drive

San Jose CALIFORNIA US

CEO: Reza Zadno

Employees: 756

PRCT Company Website

PRCT Investor Relations

Phone: 16502329832

PROCEPT BIOROBOTICS CORP / PRCT FAQ

What does PRCT do?

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 756 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.


What is the current price of PRCT stock?

The current stock price of PRCT is 31.455 USD. The price increased by 2.86% in the last trading session.


Does PRCT stock pay dividends?

PRCT does not pay a dividend.


What is the ChartMill technical and fundamental rating of PRCT stock?

PRCT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


How is the valuation of PROCEPT BIOROBOTICS CORP (PRCT) based on its PE ratio?

PROCEPT BIOROBOTICS CORP (PRCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).


Can you provide the growth outlook for PROCEPT BIOROBOTICS CORP?

The Revenue of PROCEPT BIOROBOTICS CORP (PRCT) is expected to grow by 46.32% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is the market capitalization of PRCT stock?

PROCEPT BIOROBOTICS CORP (PRCT) has a market capitalization of 1.76B USD. This makes PRCT a Small Cap stock.